Transcoronary ablation of septal hypertrophy (TASH) in HOCM: A five year experience;Funf jahre TASH (transkoronare ablation der septum hypertrophie), eine bilanz

Zeitschrift fur Kardiologie

Volumn 89, Issue 6, 2000, Pages 559-564

  Kuhn, H ^a  

^a OWL University   (Germany)

Author keywords

Hypertrophic obstructive cardiomyopathy alcohol ablation; Interventional cardiology; Percutaneous intervention; TASH

Indexed keywords

ARTICLE; CATHETER ABLATION; HEART INDEX; HEART LEFT VENTRICLE PRESSURE; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; MITRAL VALVE REGURGITATION; SYNCOPE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; TREATMENT OUTCOME; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EVALUATION; FOLLOW UP; GERMANY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; METHODOLOGY; PATHOPHYSIOLOGY; REGISTER; RESEARCH; REVIEW; SCINTISCANNING; TIME;

ALCOHOL;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; ETHANOL; EVALUATION STUDIES; FOLLOW-UP STUDIES; GERMANY; HEMODYNAMIC PROCESSES; HUMANS; REGISTRIES; RESEARCH; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034201819     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003920070228     Document Type: Article

References (42)

1. 1. Bahl VK, Chandra S, Chopra AK (1996) Septal coronary artery ablation for hypertrophic obstructive cardiomyopathy. Indian Heart J 48:701-703
2. 2. Bhargava B, Aggarval R, Kaul U, Manchanda SC, Wasir HS (1997) Transcatheter alcohol ablation of the septum in a patient of hypertrophic obstructive cardiomyopathy. Cathet Cardiovasc Diagn 41:56
3. 3. Boekstegers P, Steinbigler P, Schwaibelmair M, Steinbeck G (1998) Small but correctly localized myocardial infarctions induced by transcoronary alcohol ablation are associated with a high efficacy and a low complication rate in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J 19 (Abstr Suppl):12
4. 4. Braunwald E (1997) A new treatment for hypertrophic cardiomyopathy? Eur Heart J 18, 709-710
5. 5. Brugada P, De Swart H, Smeets ILRM, Wellens HJJ (1989) Transcoronary chemical ablation of ventricular tachycardia. Circulation 79:475-482
6. 6. Cheng TO (1999) Complete heart block complicating alcohol septal ablation For hypertrophic cardiomyopathy. Tex Heart Inst J 26:100
7. 7. Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 98:2415-2421
8. 8. Faber L, Ziemssen P, Schlichting J, Horstkotte D. Seggewiss H (1999) Perkutane transluminale septale Myokardablation (PTSMA) bei hypertropher obstruktiver Kardiomyopathie (HOCM): Analyse der Patienten mit unzureichender Reduktion des Ausflussbahngradienten (LVOTG). Z Kardiol 88 (Suppl 2):95
9. 9. Gaspar J, Martinez-Rios MA, von der Walde C, Rosas M, Ban-Hajashi E, Eidl-Lidt G, Kuri J (1999) Pericardium covered stent for septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Kath Cardiovasc Intervent 47:73-79
10. 10. Gietzen F, Leuner C, Gerenkamp T, Kuhn H (1994) Abnahme der Obstruktion bei hypertrophischer Kardiomyopathie während passagerer Okklusion des ersten Septalastes der linken Koronararterie. Z Kardiol 83 (abstr Suppl 1) 146
11. 11. Gietzen F, Leuner Ch, Gerenkamp Th, Kuhn H (1996) Katheterinterventionelle Therapie der hypertrophisch o bstruktiven Kardiomyopathie durch Alkohol-ablation des ersten Septalastes der linken Koronararterie (Abstract). Z Kardiol 85(Suppl 2):3
12. 12. Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Müller C, Kuhn HJ (1999) Acute and long-term results after transcoronary ablation of septum hypertrophy (TASH). A catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 20:1342-1354
13. 13. Gietzen FH, Leuner ChJ, Hegselmann J, Strunk-Müller C, Kuhn HJ (1999) Transcoronary ablation of septum hypertrophy (TASH) by selective septal branch injection. A four year experience in catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Circulation Suppl I, 100:1-76
14. 14. Gietzen FH, Leuner Ch, Hegselmann J, Strunk-Müller C, Kuhn H (2000) (correspondence). Eur Heart J (in press)
15. 15. Henein MY, O'Sullivan CA, Ramzy IS, Sigwart U, Gibson DG (1999) Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 34:1117-1122
16. 16. Kim JJ, Lee CW, Park SW, Hong MK, Lim HY, Song JK, Jin YS, Park SJ (1999) Improvement in exercise capacity and exercise blood pressure responds after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol 83:1220-1223
17. 17. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Hurrington D, Fassbender D, Gleichmann U, Sigwart U (1997) Non-surgical septum reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 95:2075-2081
18. 18. Kuhn H (1995) Neue Aspekte in der Behandlung hypertrophischer und dilatativer Kardiomyopathien, Kardiomyopathie - Symposium Kassel
19. 19. Kuhn H (1998) Transkoronare Ablation der Septum-Hypertrophie (TASH) Bericht über das 1. Bielefelder Werkstattgespräch. Z Kardiol 87:244-248
20. 20. Kuhn H, Gietzen F, Leuner Ch, Gerenkamp T (1997) Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment. Eur Heart J 18:846-851
21. 21. Kuhn H (1998) Induced septal infarction/non surgical septal reduction for hypertrophic obstructive cardiomyopathy Circulation 97:708-709
22. 22. Kuhn H, Gietzen F, Jachmann E, Gockel B, Freick M (1999) Die Bedeutung der Belastungsdopplerechokardiographie bei HOCM für die Behandlung mittels transkoronarer Ablation der Septumhypertrophie (TASH). Z Kardiol 88.1:138
23. 23. Kuhn H, Gietzen F, Schäfers M, Freick M, Gockel B, Strunk-Müller C, Jachmann E, Schober O (1999) Changes of left ventricular outflow tract after transcoronary ablation of septum hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transesophageal echocardiography and measuring of myocardial glucose utilization and perfusion. Eur Heart J 20:1808-1817
24. 24. Kuhn H, Gietzen F (1999) Transkoronare Ablation der Septumhypertrophie (TASH): Ersetzt sie die Operation (Myektomie)? Herz 24:647-651
25. 25. Kuhn H, Gietzen FH, Leuner CH, Schäfers M, Schober O, Strunck-Müller C, Freick M, Gockel B, Obergassel L, Lieder F, Raute-Kreinsen U (2000) Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 89 (Suppl 4):41-54
26. 26. Kusmierczyk-Droszcz B, Ruzyllo W, Choinowska L, Demkow M, Witkowski A, Karcz M, Rydlewska-Sadowska W (1998) Does myocardial contrast echocardiography identify patients at risk for heart block after transcoronary ablation of septum hypertrophy? Eur Heart J (Abstr Suppl) 19:215
27. 27. Lakkis N, Kleiman N, Killip D, Spencer WH III (1997) Hypertrophic obstructive cardiomyopathy: alternative therapeutic options. Clin Cardiol 20:417-418
28. 28. Lakkis NM, Nagueh SF, Kleiman NS, Killip D, He ZX, Verani MS, Roberts R, Spencer WH (1998) Echocardiography - guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 98:1750-1755
29. 29. Loogen F, Kuhn H, Gietzen F, Lösse B, Schulte D, Bircks W (1983) Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic non-obstructive cardiomyopathy. Eur Heart J 4 (Suppl F):145-153
30. 30. Meissner A, Krater L, Faber L, Seggewiss H (1999) 2-Jahresverlauf nach Kathetertherapie (PTSMA) bei hypertropher obstruktiver Kardiomyopathie (HOCM) Z Kardiol 88 (Suppl 2):95
31. 31. Nagueh SF, Lakkis NM, He ZX, Middleton KJ, Killip D, Zoghbi WA, Quinones MA, Roberts R, Verani MS, Kleiman NS, Spencer WH (1998) Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 32:225-229
32. 32. Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Zoghbi WA, Quinones MA, Spencer WH (1999) Changes in left ventricular filling and left atrial function six months after non surgical septal reduction therapy for hypertrophi obstructive cardiomyopathy. J Am Coll Cardiol 34:1123-1128
33. 33. Sakakibara M, Abe S, Fusegava Y, Nakajiama T, Iwata O, Goto S, Shiina Y, Handa S (1999) Percutaneous transluminal septal ablation with ethanol in hypertrophic obstructive cardiomyopathy: a case report. J Cardiol 34:35-40
34. 34. Schäfers M, Dutka D, Rhodes CD, Lammertsma AA, Hermansen F, Schober O, Kamici PG (1998) Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyoapthy. Circ Res 82:57-62
35. 35. Schulte HD, Gramsch-Zabel H, Schwartzkopff R (1995) Hypertrophic obstructive cardiomyopathy (HOCM): surgical management. Schweiz Med Wochenschr 125:1940-1949
36. 36. Schulz-Menger J, Strohm O, Waigand J, Uhlich F, Dietz R, Friedrich MG (2000) The value of magnetic resonance imaging of the left ventricular outflow tract in patients with hypertrophic obstructive cardiomyopathy after septal artery embolization. Circulation 101:1764-1766
37. 37. Seggewiss H, Faber L, Gleichmann U (1999) Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc. Surg. 47:94-100
38. 38. Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211-214
39. 39. Song JK, Kang DH, Kim JJ, Lee CW, Hong MK, Park SW, Park SJ (1999) Dobutamine stress echocardiography after transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 100:1-76
40. 40. Spirito P, Maron BI (1999) Perspectives of the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 33:1071-1075
41. 41. uhlich F, Waigand J, Gross CM, Pilz B, Schulz-Menger JE, Dietz, R (1999) Partikelembolisalion statt Alkoholablation - eine Alternative in der Katheterbehandlung der HOCM. Z Kardiol 88 Suppl 1:138
42. 42. Vogt A, Grube E, Glunz HG, Hauptmann KE, Sechtem U, Maürer W, Tebbe U, Heinrich KW, Engel HJ, Kettner W, Krawietz W, Neuhaus KL, For the Arbeitsgemeinschaft Leitende Kardiologische Krankenhaus Ärzte (ALKK) (2000). Determinants of mortality after cardiac surgery: results of the registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhaus Ärzte (ALKK) on 10525 patients. Eur Heart J 21:28-32